EUVIMEDEUVIMED entdecken
Crossref

For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?

Heather Walker

Cochrane Clinical Answers · 29.07.2026

DOI: 10.1002/cca.4802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cochrane Clinical Answers, online erschienen am 29.07.2026. Verfasst von Heather Walker. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Walker, H. (2026). For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.4802

Vancouver

Walker H. For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?. Cochrane Clinical Answers. 2026. doi:10.1002/cca.4802

BibTeX
@article{Walker2026,
  author = {Walker, Heather},
  title = {For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?},
  journal = {Cochrane Clinical Answers},
  year = {2026},
  doi = {10.1002/cca.4802}
}
Kostenlos starten →